Article Text

Download PDFPDF
Original article
Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction
  1. Matthias Schwenkglenks1,2,
  2. Toby J Toward3,
  3. Stephanie Plent3,
  4. Thomas D Szucs1,
  5. Daniel J Blackman4,
  6. Andreas Baumbach5
  1. 1Institute of Pharmaceutical Medicine (ECPM), University of Basel, Basel, Switzerland
  2. 2Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland
  3. 3The Medicines Company, Abingdon, UK
  4. 4Leeds General Infirmary, Leeds, UK
  5. 5Bristol Heart Institute, Bristol, UK
  1. Correspondence to Dr Matthias Schwenkglenks, University of Basel, Institute of Pharmaceutical Medicine (ECPM), Klingelbergstrasse 61, 4056 Basel, Switzerland; m.schwenkglenks{at}unibas.ch

Footnotes

  • Funding This research was funded by The Medicines Company, Parsippany, NJ, USA. It was performed to inform a Single Technology Appraisal by the National Institute for Health and Clinical Excellence.

  • Competing interests MS received consultancy fees and research funding from The Medicines Company via employment institution. TT and SP were employees of The Medicines Company at the time of study conduct. TDS has no conflict of interest. DB and AB received speaker's fees and research grants from The Medicines Company.

  • Ethics approval This health economic study did not involve human subjects but underlying data sources did. This is also true for the HORIZONS-AMI trial (ClinicalTrials.gov number, NCT00433966) that formed the main clinical basis of the analysis. Ethical approval for the HORIZONS-AMI trial was obtained as reported in the clinical publications referenced in the article.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement A substantial amount of additional data and details relating to the clinical and economic aspects of the study are contained in the evaluation report underlying NICE guidance TA230. They are available to the general public from the NICE website (http://guidance.nice.org.uk/TA/Wave23/27/FAD/EvaluationReport).

View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding This research was funded by The Medicines Company, Parsippany, NJ, USA. It was performed to inform a Single Technology Appraisal by the National Institute for Health and Clinical Excellence.

  • Competing interests MS received consultancy fees and research funding from The Medicines Company via employment institution. TT and SP were employees of The Medicines Company at the time of study conduct. TDS has no conflict of interest. DB and AB received speaker's fees and research grants from The Medicines Company.

  • Ethics approval This health economic study did not involve human subjects but underlying data sources did. This is also true for the HORIZONS-AMI trial (ClinicalTrials.gov number, NCT00433966) that formed the main clinical basis of the analysis. Ethical approval for the HORIZONS-AMI trial was obtained as reported in the clinical publications referenced in the article.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement A substantial amount of additional data and details relating to the clinical and economic aspects of the study are contained in the evaluation report underlying NICE guidance TA230. They are available to the general public from the NICE website (http://guidance.nice.org.uk/TA/Wave23/27/FAD/EvaluationReport).

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.